Pharmacopeia

The biopharmaceutical company Pharmacopeia is focused on addressing critical medical needs through therapeutic discoveries and developments. It has a diverse internal program portfolio, including PS433540, a dual-acting angiotensin and endothelin receptor antagonist, and PS178990, a muscle-selective SARM agonist, both in clinical development stages. The company’s pipeline also includes PS031291, a preclinical product targeting multiple myeloma and inflammatory conditions, and JAK3 inhibitors for dermatologic and ocular diseases. Pharmacopeia has strategically aligned with major pharmaceutical entities such as Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. Established in 1993 as Pharmacopeia Drug Discovery, Inc., and later renamed in 2007, the company operates as a subsidiary of Ligand Pharmaceuticals Inc. in Cranbury, New Jersey. In 27 July 2005, the company secured a $7.63M Venture Round investment from Senvest Capital, Highbridge Capital Management, Iroquois Capital, ClearArc Capital, Nite Capital Management, Clarion Capital Partners, Carpe Diem Capital Management, Downsview Capital, and Balyasny Asset Management.